

## TherapyMonitor Multiple Myeloma (MM) HY2 2025

### SYNOPSIS

Objective	<p><u>Primary Objective:</u></p> <ul style="list-style-type: none"> <li>• Description of demographic characteristics, clinical features, and treatment courses of patients with MM in real-world clinical practice.</li> </ul> <p><u>Secondary Objective:</u></p> <ul style="list-style-type: none"> <li>• Identification and quantification of subgroups with specific treatment algorithms based on individual patient characteristics, diagnostic parameters, biomarkers, cytogenetic aberrations, and clinical features as well as prior therapeutic interventions.</li> </ul>
Patient population	<p>The inclusion criteria for <b>newly documented patients</b> are:</p> <ul style="list-style-type: none"> <li>• Diagnosis of a multiple myeloma</li> <li>• The patient presented with a therapy relevant event* in the second half of 2025 (01.07.2025 – 31.12.2025)</li> <li>• Patient age <math>\geq</math> 18 years</li> </ul> <p><b>Update of all previous patient documentation from earlier data collection periods</b></p> <ul style="list-style-type: none"> <li>• <b>Follow-up</b> with or without a therapy relevant event* in HY2 2025</li> <li>• <b>Drop-out</b> (information that the patient was transferred to another center or was a no-show)</li> <li>• <b>Death</b> of the patient (irrespective of the time period)</li> </ul> <p>*A therapy relevant event is defined as: start, modification, or end of a therapeutic intervention (induction, SCT, maintenance, CAR-T) or death of the patient (irrespective of time period)</p>
Study design / Methodology	<p>Collection of the complete treatment course</p> <ul style="list-style-type: none"> <li>✓ retrospectively from the current point back to the initial diagnosis and,</li> <li>✓ anonymized</li> </ul> <p>in an indication-specific electronic case report form (eCRF) based on the patient record.</p>

Statistical Analysis	Descriptive analysis of treatment algorithms as well as of the primary and secondary objectives. Analyses of outcome (treatment duration, time to next treatment, and overall survival) using Kaplan-Meier methods, with and without strata (tested using the log-rank test).
Sample Size	<p><u>Patients:</u> The goal is to create a representative sample that covers approximately 10% of the treated prevalence in Germany.</p> <p><u>Treatment centers:</u> A total of ~50 centers, stratified across university hospitals, non-university hospitals, and office-based practices according to the distribution of the MM population.</p>